Abstract
Background: Intractable pancreatic pain is one of the most common symptoms of patients with pancreatic ductal adenocarcinoma (PDAC). Celiac neurolysis (CN) and splanchnicectomy were already described as effective methods to manage abdominal pain in unresectable PDAC, but their impact on overall survival (OS) has not yet been established. Objective: We aimed to investigate the impact of CN and splanchnicectomy on the survival of patients with unresectable pancreatic cancer. Methods: A systematic review of PubMed and Cochrane Library according to predefined searching terms was conducted in March 2020. Hazard ratios (HR) of OS data were calculated using the Mantel-Haenszel model for random effects or fixed effects. Result: Four randomized-controlled trials (RCTs) and 2 non-RCTs with a total of 2,507 patients were identified. The overall pooled HR did not reveal any relevant effect of CN and splanchnicectomy on OS (HR: 1.03; 95% CI: 0.81–1.32), which was also underlined by the sensitivity analysis of RCTs (HR: 1.0; 95% CI: 0.72–1.39) and non-RCTs (HR: 1.07; 95% CI: 0.71–1.63). However, subgroup analyses depending on tumor stage revealed that CN or splanchnicectomy was associated with a worsened OS in AJCC (American Joint Committee on Cancer) stage III patients with unresectable PDAC (HR: 1.22; 95% CI: 1.03–1.45), but nor for AJCC stage IV patients (HR: 1.27; 95% CI: 0.9–1.80). Conclusion: Although only few data are currently available, this systematic review with meta-analysis showed that in unresectable PDAC, CN or splanchnicectomy is associated with a worsened survival in stage III PDAC patients, with no effect on stage IV PDAC patients. These data call for caution in the usage of CN or splanchnicectomy in stage III PDAC and for further studies addressing this observation.
References
1.
Rawla
P
, Sunkara
T
, Gaduputi
V
. Epidemiology of pancreatic cancer: global trends, etiology and risk factors
. World J Oncol
. 2019
;10
(1
):10
–27
. .2.
Watanabe
I
, Sasaki
S
, Konishi
M
, Nakagohri
T
, Inoue
K
, Oda
T
, Onset symptoms and tumor locations as prognostic factors of pancreatic cancer
. Pancreas
. 2004
;28
:160
–5
.3.
Balaban
EP
, Mangu
PB
, Khorana
AA
, Shah
MA
, Mukherjee
S
, Crane
CH
, Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline
. J Clin Oncol
. 2016
;34
(22
):2654
–68
.4.
Lakatos
G
, Balazs
A
, Kui
B
, Godi
S
, Szucs
A
, Szentesi
A
, Pancreatic cancer: multicenter prospective data collection and analysis by the Hungarian Pancreatic Study Group
. J Gastrointestin Liver Dis
. 2016
;25
(2
):219
–25
.5.
Koulouris
AI
, Banim
P
, Hart
AR
. Pain in patients with pancreatic cancer: prevalence, mechanisms, management and future developments
. Dig Dis Sci
. 2017
;62
(4
):861
–70
. .6.
Ceyhan
GO
, Bergmann
F
, Kadihasanoglu
M
, Altintas
B
, Demir
IE
, Hinz
U
, Pancreatic neuropathy and neuropathic pain: a comprehensive pathomorphological study of 546 cases
. Gastroenterology
. 2009
;136
(1
):177
–86 e1
.7.
Demir
IE
, Mota Reyes
C
. Chemokines: the (un)usual suspects in pancreatic cancer neural invasion
. Nat Rev Gastroenterol Hepatol
. 2021
;18
(4
):221
–2
.8.
Spiegel
D
, Sands
S
, Koopman
C
. Pain and depression in patients with cancer
. Cancer
. 1994
;74
(9
):2570
–8
. .9.
Mantyh
PW
. Cancer pain and its impact on diagnosis, survival and quality of life
. Nat Rev Neurosci
. 2006
;7
(10
):797
–809
. .10.
Zheng
J
, He
J
, Wang
W
, Zhou
H
, Cai
S
, Zhu
L
, The impact of pain and opioids use on survival in cancer patients: results from a population-based cohort study and a meta-analysis
. Medicine
. 2020
;99
(9
):e19306
.11.
Smith
TJ
, Coyne
PJ
, Staats
PS
, Deer
T
, Stearns
LJ
, Rauck
RL
, An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)
. Ann Oncol
. 2005
;16
(5
):825
–33
.12.
Drewes
AM
, Campbell
CM
, Ceyhan
GO
, Delhaye
M
, Garg
PK
, van Goor
H
, Pain in pancreatic ductal adenocarcinoma: a multidisciplinary, international guideline for optimized management
. Pancreatology
. 2018
;18
(4
):446
–57
.13.
Dobosz
Ł
, Kaczor
M
, Stefaniak
TJ
. Pain in pancreatic cancer: review of medical and surgical remedies
. ANZ J Surg
. 2016
;86
(10
):756
–61
. .14.
Hameed
M
, Hameed
H
, Erdek
M
. Pain management in pancreatic cancer
. Cancers
. 2010
;3
(1
):43
–60
. .15.
Sachdev
AH
, Gress
FG
. Celiac plexus block and neurolysis: a review
. Gastrointest Endosc Clin N Am
. 2018
;28
(4
):579
–86
. .16.
Wyse
JM
, Carone
M
, Paquin
SC
, Usatii
M
, Sahai
AV
. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer
. J Clin Oncol
. 2011
;29
(26
):3541
–6
. .17.
Mercadante
S
. Celiac plexus block versus analgesics in pancreatic cancer pain
. Pain
. 1993
;52
(2
):187
–92
. .18.
Puli
SR
, Reddy
JB
, Bechtold
ML
, Antillon
MR
, Brugge
WR
. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review
. Dig Dis Sci
. 2009
;54
(11
):2330
–7
. .19.
Zhang
CL
, Zhang
TJ
, Guo
YN
, Yang
LQ
, He
MW
, Shi
JZ
, Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain
. Dig Dis Sci
. 2008
;53
(3
):856
–60
.20.
Wong
GY
, Schroeder
DR
, Carns
PE
, Wilson
JL
, Martin
DP
, Kinney
MO
, Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial
. JAMA
. 2004
;291
(9
):1092
–9
.21.
Lavu
H
, Lengel
HB
, Sell
NM
, Baiocco
JA
, Kennedy
EP
, Yeo
TP
, A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma
. J Am Coll Surg
. 2015
;220
(4
):497
–508
.22.
Nagels
W
, Pease
N
, Bekkering
G
, Cools
F
, Dobbels
P
. Celiac plexus neurolysis for abdominal cancer pain: a systematic review
. Pain Med
. 2013
;14
(8
):1140
–63
. .23.
Ambai
VT
, Singh
V
, Boorman
DW
, Neufeld
NJ
. Celiac plexus neurolysis for abdominal cancers: going beyond pancreatic cancer pain
. Pain Rep
. 2021
;6
(1
):e930
. .24.
Gardner
AM
, Solomou
G
. Relief of the pain of unresectable carcinoma of pancreas by chemical splanchnicectomy during laparotomy
. Ann R Coll Surg Engl
. 1984
;66
(6
):409
–11
.25.
Lillemoe
KD
, Cameron
JL
, Kaufman
HS
, Yeo
CJ
, Pitt
HA
, Sauter
PK
, Chemical splanchnicectomy in patients with unresectable pancreatic-cancer: a prospective randomized trial
. Ann Surg
. 1993
;217
(5
):447
–57
.26.
Oh
TK
, Lee
WJ
, Woo
SM
, Kim
NW
, Yim
J
, Kim
DH
. Impact of celiac plexus neurolysis on survival in patients with unresectable pancreatic cancer: a retrospective, propensity score matching analysis
. Pain Physician
. 2017
;20
(3
):E357
–65
.27.
Fujii-Lau
LL
, Bamlet
WR
, Eldrige
JS
, Chari
ST
, Gleeson
FC
, Abu Dayyeh
BK
, Impact of celiac neurolysis on survival in patients with pancreatic cancer
. Gastrointest Endosc
. 2015
;82
(1
):46
–56.e2
.28.
Dong
D
, Zhao
M
, Zhang
J
, Huang
M
, Wang
Y
, Qi
L
, Neurolytic splanchnic nerve block and pain relief, survival, and quality of life in unresectable pancreatic cancer: a randomized controlled trial
. Anesthesiology
. 2021
;135
(4
):686
–98
.29.
Yan
BM
, Myers
RP
. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer
. Am J Gastroenterol
. 2007
;102
(2
):430
–8
. .30.
Stang
A
. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
. Eur J Epidemiol
. 2010
;25
(9
):603
–5
. .31.
Tierney
JF
, Stewart
LA
, Ghersi
D
, Burdett
S
, Sydes
MR
. Practical methods for incorporating summary time-to-event data into meta-analysis
. Trials
. 2007
;8
:16
. .32.
Sterne
J
, Egger
M
, Moher
D
. Addressing reporting biases
. In: Higgins
JPT
, Green
S
, editors. Cochrane handbook for systematic reviews of interventions
. Chichester
: Wiley
; 2008
. p. 297
–333
.33.
Kappis
M
. Erfahrungen mit local anasthesie bie bauchoperationen
. Vehr Dtsch Gesellsch Chir
. 1914
;43
:87
–9
.34.
Doi
S
, Yasuda
I
, Kawakami
H
, Hayashi
T
, Hisai
H
, Irisawa
A
, Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial
. Endoscopy
. 2013
;45
(5
):362
–9
.35.
Luz
LP
, Al-Haddad
MA
, DeWitt
JA
. EUS-guided celiac plexus interventions in pancreatic cancer pain: an update and controversies for the endosonographer
. Endosc Ultrasound
. 2014
;3
(4
):213
–20
. .36.
Puli
SR
, Reddy
JB
, Bechtold
ML
, Antillon
MR
, Brugge
WR
. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review
. Dig Dis Sci
. 2009
;54
(11
):2330
–7
. .37.
Kaufman
M
, Singh
G
, Das
S
, Concha-Parra
R
, Erber
J
, Micames
C
, Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer
. J Clin Gastroenterol
. 2010
;44
(2
):127
–34
.38.
Koulouris
AI
, Alexandre
L
, Hart
AR
, Clark
A
. Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) technique and analgesic efficacy in patients with pancreatic cancer: a systematic review and meta-analysis
. Pancreatology
. 2021
;21
(2
):434
–42
. .39.
Asif
AA
, Walayat
SK
, Bechtold
ML
, Revanur
V
, Puli
SR
. EUS-guided celiac plexus neurolysis for pain in pancreatic cancer patients: a meta-analysis and systematic review
. J Community Hosp Intern Med Perspect
. 2021
;11
(4
):536
–42
. .40.
Renz
BW
, Takahashi
R
, Tanaka
T
, Macchini
M
, Hayakawa
Y
, Dantes
Z
, β2 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer
. Cancer Cell
. 2018
;33
(1
):75
–90.e7
.41.
Bastos
DB
, Sarafim-Silva
BAM
, Sundefeld
MLMM
, Ribeiro
AA
, Brandão
JDP
, Biasoli
ÉR
, Circulating catecholamines are associated with biobehavioral factors and anxiety symptoms in head and neck cancer patients
. PLoS One
. 2018
;13
(8
):e0202515
.42.
Behrns
KE
. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
. Yearbook of surgery
. 2012
. Vol. 2012
; p. 243
–4
. .43.
Lambert
A
, Schwarz
L
, Borbath
I
, Henry
A
, Van Laethem
JL
, Malka
D
, An update on treatment options for pancreatic adenocarcinoma
. Ther Adv Med Oncol
. 2019
;11
:1758835919875568
.44.
Wiechowska-Kozlowska
A
, Boer
K
, Wojcicki
M
, Milkiewicz
P
. The efficacy and safety of endoscopic ultrasound-guided celiac plexus neurolysis for treatment of pain in patients with pancreatic cancer
. Gastroenterol Res Pract
. 2012
;2012
:503098
.45.
Lee
JM
. CT-guided celiac plexus block for intractable abdominal pain
. J Korean Med Sci
. 2000
;15
(2
):173
–8
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
